Last reviewed · How we verify

NCT05364086: DiRECT

An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study

Active, enrolled Last updated 13 March 2026
What this trial tests

trial testing Biospecimen Collection in Hematopoietic and Lymphoid Cell Neoplasm in 2,100 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
26 April 2022
Primary endpoint
31 October 2026
31 January 2030

Quick facts

Lead sponsorUniversity of Rochester NCORP Research Base
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment2,100
Start date26 April 2022
Primary completion31 October 2026
Estimated completion31 January 2030
Sites259 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Rochester NCORP Research Base

Who can join

18 and older, any sex, with Hematopoietic and Lymphoid Cell Neoplasm or Malignant Solid Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study compares treatment outcomes between patients of African American/Black (AA) ancestry and European American/White (EA) ancestry currently receiving immune checkpoint inhibitor treatment. Collecting samples of blood and saliva and health and treatment information from racially diverse patients receiving immune checkpoint inhibitor treatment over time may help doctors better understand health care disparities among all cancer patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Under-Representation and Under-Reporting of Minoritized Racial and Ethnic Groups in Clinical Trials on Immune Checkpoint Inhibitors.
    Chua AV, Delmerico J, Sheng H, Huang XW, et al · · 2025 · cited 6× · PMID 39173090 · DOI 10.1200/op.24.00033

Verify or expand the search:

Other trials of Biospecimen Collection

Trials testing the same drug.

Other recruiting trials for Hematopoietic and Lymphoid Cell Neoplasm

Currently open trials in the same condition.

Other University of Rochester NCORP Research Base trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05364086.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing